Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jan 15;99(2):297–304. doi: 10.1172/JCI119158

Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness.

P J Malloy 1, T R Eccleshall 1, C Gross 1, L Van Maldergem 1, R Bouillon 1, D Feldman 1
PMCID: PMC507797  PMID: 9005998

Abstract

Mutations in the vitamin D receptor (VDR) result in target organ resistance to 1alpha,25-dihydroxyvitamin D [1,25(OH)2D3], the active form of vitamin D, and cause hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR). We analyzed the VDR of a patient who exhibited three genetic diseases: HVDRR, congenital total lipodystrophy, and persistent mullerian duct syndrome. The patient was treated with extremely high dose calcitriol (12.5 microg/d) which normalized serum calcium and improved his rickets. Analysis of [3H]1,25(OH)2D3 binding in the patient's cultured fibroblasts showed normal abundance of VDR with only a slight decrease in binding affinity compared to normal fibroblasts when measured at 0 degrees C. The patient's fibroblasts demonstrated 1,25(OH)2D3-induction of 24-hydroxylase mRNA, but the effective dose was approximately fivefold higher than in control cells. Sequence analysis of the patient's VDR gene uncovered a single point mutation, H305Q. The recreated mutant VDR was transfected into COS-7 cells where it was 5 to 10-fold less responsive to 1,25(OH)2D3 in gene transactivation. The mutant VDR had an eightfold lower affinity for [3H]1,25(OH)2D3 than the normal VDR when measured at 24 degrees C. RFLP demonstrated that the patient was homozygous for the mutation while the parents were heterozygous. In conclusion, we describe a new ligand binding domain mutation in the VDR that causes HVDRR due to decreased affinity for 1,25(OH)2D3 which can be effectively treated with extremely high doses of hormone.

Full Text

The Full Text of this article is available as a PDF (339.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker A. R., McDonnell D. P., Hughes M., Crisp T. M., Mangelsdorf D. J., Haussler M. R., Pike J. W., Shine J., O'Malley B. W. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A. 1988 May;85(10):3294–3298. doi: 10.1073/pnas.85.10.3294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balsan S., Garabédian M., Larchet M., Gorski A. M., Cournot G., Tau C., Bourdeau A., Silve C., Ricour C. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest. 1986 May;77(5):1661–1667. doi: 10.1172/JCI112483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beer S., Tieder M., Kohelet D., Liberman O. A., Vure E., Bar-Joseph G., Gabizon D., Borochowitz Z. U., Varon M., Modai D. Vitamin D resistant rickets with alopecia: a form of end organ resistance to 1,25 dihydroxy vitamin D. Clin Endocrinol (Oxf) 1981 Apr;14(4):395–402. doi: 10.1111/j.1365-2265.1981.tb00626.x. [DOI] [PubMed] [Google Scholar]
  4. Bliziotes M., Yergey A. L., Nanes M. S., Muenzer J., Begley M. G., Vieira N. E., Kher K. K., Brandi M. L., Marx S. J. Absent intestinal response to calciferols in hereditary resistance to 1,25-dihydroxyvitamin D: documentation and effective therapy with high dose intravenous calcium infusions. J Clin Endocrinol Metab. 1988 Feb;66(2):294–300. doi: 10.1210/jcem-66-2-294. [DOI] [PubMed] [Google Scholar]
  5. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature. 1995 Jun 1;375(6530):377–382. doi: 10.1038/375377a0. [DOI] [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  7. Brooks M. H., Bell N. H., Love L., Stern P. H., Orfei E., Queener S. F., Hamstra A. J., DeLuca H. F. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med. 1978 May 4;298(18):996–999. doi: 10.1056/NEJM197805042981804. [DOI] [PubMed] [Google Scholar]
  8. Chen T. L., Hirst M. A., Cone C. M., Hochberg Z., Tietze H. U., Feldman D. 1,25-dihydroxyvitamin D resistance, rickets, and alopecia: analysis of receptors and bioresponse in cultured fibroblasts from patients and parents. J Clin Endocrinol Metab. 1984 Sep;59(3):383–388. doi: 10.1210/jcem-59-3-383. [DOI] [PubMed] [Google Scholar]
  9. Clemens T. L., Adams J. S., Horiuchi N., Gilchrest B. A., Cho H., Tsuchiya Y., Matsuo N., Suda T., Holick M. F. Interaction of 1,25-dihydroxyvitamin-D3 with keratinocytes and fibroblasts from skin of normal subjects and a subject with vitamin-D-dependent rickets, type II: a model for study of the mode of action of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab. 1983 Apr;56(4):824–830. doi: 10.1210/jcem-56-4-824. [DOI] [PubMed] [Google Scholar]
  10. Evans R. M. The steroid and thyroid hormone receptor superfamily. Science. 1988 May 13;240(4854):889–895. doi: 10.1126/science.3283939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Feldman D., Chen T., Cone C., Hirst M., Shani S., Benderli A., Hochberg Z. Vitamin D resistant rickets with alopecia: cultured skin fibroblasts exhibit defective cytoplasmic receptors and unresponsiveness to 1,25(OH)2D3. J Clin Endocrinol Metab. 1982 Nov;55(5):1020–1022. doi: 10.1210/jcem-55-5-1020. [DOI] [PubMed] [Google Scholar]
  12. Feldman D., Malloy P. J. Hereditary 1,25-dihydroxyvitamin D resistant rickets: molecular basis and implications for the role of 1,25(OH) 2D3 in normal physiology. Mol Cell Endocrinol. 1990 Sep 10;72(3):C57–C62. doi: 10.1016/0303-7207(90)90137-w. [DOI] [PubMed] [Google Scholar]
  13. Forman B. M., Samuels H. H. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. Mol Endocrinol. 1990 Sep;4(9):1293–1301. doi: 10.1210/mend-4-9-1293. [DOI] [PubMed] [Google Scholar]
  14. Gamblin G. T., Liberman U. A., Eil C., Downs R. W., Jr, DeGrange D. A., Marx S. J. Vitamin D-dependent rickets type II. Defective induction of 25-hydroxyvitamin D3-24-hydroxylase by 1,25-dihydroxyvitamin D3 in cultured skin fibroblasts. J Clin Invest. 1985 Mar;75(3):954–960. doi: 10.1172/JCI111796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Griffin J. E., Zerwekh J. E. Impaired stimulation of 25-hydroxyvitamin D-24-hydroxylase in fibroblasts from a patient with vitamin D-dependent rickets, type II. A form of receptor-positive resistance to 1,25-dihydroxyvitamin D3. J Clin Invest. 1983 Oct;72(4):1190–1199. doi: 10.1172/JCI111074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hewison M., Rut A. R., Kristjansson K., Walker R. E., Dillon M. J., Hughes M. R., O'Riordan J. L. Tissue resistance to 1,25-dihydroxyvitamin D without a mutation of the vitamin D receptor gene. Clin Endocrinol (Oxf) 1993 Dec;39(6):663–670. doi: 10.1111/j.1365-2265.1993.tb02424.x. [DOI] [PubMed] [Google Scholar]
  17. Hijiya N., Setoguchi M., Matsuura K., Higuchi Y., Akizuki S., Yamamoto S. Cloning and characterization of the human osteopontin gene and its promoter. Biochem J. 1994 Oct 1;303(Pt 1):255–262. doi: 10.1042/bj3030255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hirst M. A., Hochman H. I., Feldman D. Vitamin D resistance and alopecia: a kindred with normal 1,25-dihydroxyvitamin D binding, but decreased receptor affinity for deoxyribonucleic acid. J Clin Endocrinol Metab. 1985 Mar;60(3):490–495. doi: 10.1210/jcem-60-3-490. [DOI] [PubMed] [Google Scholar]
  19. Hochberg Z., Benderli A., Levy J., Vardi P., Weisman Y., Chen T., Feldman D. 1,25-Dihydroxyvitamin D resistance, rickets, and alopecia. Am J Med. 1984 Nov;77(5):805–811. doi: 10.1016/0002-9343(84)90516-3. [DOI] [PubMed] [Google Scholar]
  20. Hochberg Z., Gilhar A., Haim S., Friedman-Birnbaum R., Levy J., Benderly A. Calcitriol-resistant rickets with alopecia. Arch Dermatol. 1985 May;121(5):646–647. [PubMed] [Google Scholar]
  21. Hughes M. R., Malloy P. J., Kieback D. G., Kesterson R. A., Pike J. W., Feldman D., O'Malley B. W. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science. 1988 Dec 23;242(4886):1702–1705. doi: 10.1126/science.2849209. [DOI] [PubMed] [Google Scholar]
  22. Hughes M. R., Malloy P. J., O'Malley B. W., Pike J. W., Feldman D. Genetic defects of the 1,25-dihydroxyvitamin D3 receptor. J Recept Res. 1991;11(1-4):699–716. doi: 10.3109/10799899109066437. [DOI] [PubMed] [Google Scholar]
  23. Kikuchi K., Okamoto T., Nishino M., Takeda E., Kuroda Y., Miyao M. Vitamin D-dependent rickets type II: report of three cases. ASDC J Dent Child. 1988 Nov-Dec;55(6):465–468. [PubMed] [Google Scholar]
  24. Koeffler H. P., Bishop J. E., Reichel H., Singer F., Nagler A., Tobler A., Walka M., Norman A. W. Lymphocyte cell lines from vitamin D-dependent rickets type II show functional defects in the 1 alpha,25-dihydroxyvitamin D3 receptor. Mol Cell Endocrinol. 1990 Mar 26;70(1):1–11. doi: 10.1016/0303-7207(90)90053-b. [DOI] [PubMed] [Google Scholar]
  25. Kristjansson K., Rut A. R., Hewison M., O'Riordan J. L., Hughes M. R. Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. J Clin Invest. 1993 Jul;92(1):12–16. doi: 10.1172/JCI116539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Liberman U. A., Eil C., Marx S. J. Receptor-positive hereditary resistance to 1,25-dihydroxyvitamin D: chromatography of hormone-receptor complexes on deoxyribonucleic acid-cellulose shows two classes of mutation. J Clin Endocrinol Metab. 1986 Jan;62(1):122–126. doi: 10.1210/jcem-62-1-122. [DOI] [PubMed] [Google Scholar]
  27. Lin N. U., Malloy P. J., Sakati N., al-Ashwal A., Feldman D. A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab. 1996 Jul;81(7):2564–2569. doi: 10.1210/jcem.81.7.8675579. [DOI] [PubMed] [Google Scholar]
  28. Malloy P. J., Hochberg Z., Pike J. W., Feldman D. Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. J Clin Endocrinol Metab. 1989 Feb;68(2):263–269. doi: 10.1210/jcem-68-2-263. [DOI] [PubMed] [Google Scholar]
  29. Malloy P. J., Hochberg Z., Tiosano D., Pike J. W., Hughes M. R., Feldman D. The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families. J Clin Invest. 1990 Dec;86(6):2071–2079. doi: 10.1172/JCI114944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Malloy P. J., Weisman Y., Feldman D. Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. J Clin Endocrinol Metab. 1994 Feb;78(2):313–316. doi: 10.1210/jcem.78.2.8106618. [DOI] [PubMed] [Google Scholar]
  31. Malloy P. J., Zhao X., Madani N. D., Feldman D. Cloning and expression of the gene from Candida albicans that encodes a high-affinity corticosteroid-binding protein. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1902–1906. doi: 10.1073/pnas.90.5.1902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mangelsdorf D. J., Evans R. M. The RXR heterodimers and orphan receptors. Cell. 1995 Dec 15;83(6):841–850. doi: 10.1016/0092-8674(95)90200-7. [DOI] [PubMed] [Google Scholar]
  33. Marx S. J., Bliziotes M. M., Nanes M. Analysis of the relation between alopecia and resistance to 1,25-dihydroxyvitamin D. Clin Endocrinol (Oxf) 1986 Oct;25(4):373–381. doi: 10.1111/j.1365-2265.1986.tb01703.x. [DOI] [PubMed] [Google Scholar]
  34. Ohyama Y., Noshiro M., Okuda K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS Lett. 1991 Jan 28;278(2):195–198. doi: 10.1016/0014-5793(91)80115-j. [DOI] [PubMed] [Google Scholar]
  35. Refetoff S., Weiss R. E., Usala S. J. The syndromes of resistance to thyroid hormone. Endocr Rev. 1993 Jun;14(3):348–399. doi: 10.1210/edrv-14-3-348. [DOI] [PubMed] [Google Scholar]
  36. Renaud J. P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 1995 Dec 14;378(6558):681–689. doi: 10.1038/378681a0. [DOI] [PubMed] [Google Scholar]
  37. Ritchie H. H., Hughes M. R., Thompson E. T., Malloy P. J., Hochberg Z., Feldman D., Pike J. W., O'Malley B. W. An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9783–9787. doi: 10.1073/pnas.86.24.9783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rosen J. F., Fleischman A. R., Finberg L., Hamstra A., DeLuca H. F. Rickets with alopecia: an inborn error of vitamin D metabolism. J Pediatr. 1979 May;94(5):729–735. doi: 10.1016/s0022-3476(79)80139-0. [DOI] [PubMed] [Google Scholar]
  39. Saijo T., Ito M., Takeda E., Huq A. H., Naito E., Yokota I., Sone T., Pike J. W., Kuroda Y. A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet. 1991 Sep;49(3):668–673. [PMC free article] [PubMed] [Google Scholar]
  40. Skowronski R. J., Peehl D. M., Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993 May;132(5):1952–1960. doi: 10.1210/endo.132.5.7682937. [DOI] [PubMed] [Google Scholar]
  41. Sone T., Marx S. J., Liberman U. A., Pike J. W. A unique point mutation in the human vitamin D receptor chromosomal gene confers hereditary resistance to 1,25-dihydroxyvitamin D3. Mol Endocrinol. 1990 Apr;4(4):623–631. doi: 10.1210/mend-4-4-623. [DOI] [PubMed] [Google Scholar]
  42. Sone T., Scott R. A., Hughes M. R., Malloy P. J., Feldman D., O'Malley B. W., Pike J. W. Mutant vitamin D receptors which confer hereditary resistance to 1,25-dihydroxyvitamin D3 in humans are transcriptionally inactive in vitro. J Biol Chem. 1989 Dec 5;264(34):20230–20234. [PubMed] [Google Scholar]
  43. Takeda E., Kuroda Y., Saijo T., Naito E., Kobashi H., Yokota I., Miyao M. 1 alpha-hydroxyvitamin D3 treatment of three patients with 1,25-dihydroxyvitamin D-receptor-defect rickets and alopecia. Pediatrics. 1987 Jul;80(1):97–101. [PubMed] [Google Scholar]
  44. Takeda E., Yokota I., Kawakami I., Hashimoto T., Kuroda Y., Arase S. Two siblings with vitamin-D-dependent rickets type II: no recurrence of rickets for 14 years after cessation of therapy. Eur J Pediatr. 1989 Oct;149(1):54–57. doi: 10.1007/BF02024336. [DOI] [PubMed] [Google Scholar]
  45. Van Maldergem L., Bachy A., Feldman D., Bouillon R., Maassen J., Dreyer M., Rey R., Holm C., Gillerot Y. Syndrome of lipoatrophic diabetes, vitamin D resistant rickets, and persistent Müllerian ducts in a Turkish boy born to consanguineous parents. Am J Med Genet. 1996 Aug 23;64(3):506–513. doi: 10.1002/(SICI)1096-8628(19960823)64:3<506::AID-AJMG12>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  46. Wagner R. L., Apriletti J. W., McGrath M. E., West B. L., Baxter J. D., Fletterick R. J. A structural role for hormone in the thyroid hormone receptor. Nature. 1995 Dec 14;378(6558):690–697. doi: 10.1038/378690a0. [DOI] [PubMed] [Google Scholar]
  47. Weisman Y., Bab I., Gazit D., Spirer Z., Jaffe M., Hochberg Z. Long-term intracaval calcium infusion therapy in end-organ resistance to 1,25-dihydroxyvitamin D. Am J Med. 1987 Nov;83(5):984–990. doi: 10.1016/0002-9343(87)90666-8. [DOI] [PubMed] [Google Scholar]
  48. Wiese R. J., Goto H., Prahl J. M., Marx S. J., Thomas M., al-Aqeel A., DeLuca H. F. Vitamin D-dependency rickets type II: truncated vitamin D receptor in three kindreds. Mol Cell Endocrinol. 1993 Jan;90(2):197–201. doi: 10.1016/0303-7207(93)90152-a. [DOI] [PubMed] [Google Scholar]
  49. Yagi H., Ozono K., Miyake H., Nagashima K., Kuroume T., Pike J. W. A new point mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab. 1993 Feb;76(2):509–512. doi: 10.1210/jcem.76.2.8381803. [DOI] [PubMed] [Google Scholar]
  50. al-Aqeel A., Ozand P., Sobki S., Sewairi W., Marx S. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII). Clin Endocrinol (Oxf) 1993 Aug;39(2):229–237. doi: 10.1111/j.1365-2265.1993.tb01779.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES